Clinical Trial 21383

A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Disease Site: Other Digestive Organ, Other Endocrine System

PI: Strosberg, Jonathan

Clinical Trial 22595

Disease Site: Multiple Myeloma

PI: Paba Prada, Claudia

Clinical Trial 90035

Disease Site: Unknown Sites

PI: Vargas Madueno, Fernando

Clinical Trial 22286

Disease Site: Leukemia, other

PI: Shah, Bijal

Clinical Trial 20110

GBM Agile: Global Adaptive Trial Master Protocol

Disease Site: Brain and Nervous System

PI: Grogan, Patrick

Clinical Trial 20831

A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma

Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

PI: Gaballa, Sameh

Clinical Trial 20937

A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib In Refractory Advanced Thymic Carcinoma

Disease Site: Other Respiratory and Intrathoracic Organs

PI: Tanvetyanon, Tawee

Clinical Trial 21341

A Phase II Study of Cemiplimab plus Ziv-Aflibercept for Subjects with Metastatic Uveal Melanoma

Disease Site: Eye and Orbit

PI: Tarhini, Ahmad

Clinical Trial 21143

Disease Site: Mycosis Fungoides

PI: Sokol, Lubomir

Clinical Trial 20963

A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

Disease Site: Myeloid and Monocytic Leukemia

PI: Kuykendall, Andrew

Clinical Trial 21626

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

Disease Site: Lung

PI: Gray, Jhanelle

Clinical Trial 21024

A Phase IIa Study of Dendritic Cell Vaccines against HER2/HER3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)

Disease Site: Brain and Nervous System

PI: Forsyth, Peter